文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

生物标志物在急性肾损伤中预测干预与结局:MARKISIO研究

Biomarkers in acute kidney injury settings to predict interventions and outcomes: the MARKISIO study.
PubMed 文献 · Crit Care · 2025-05-20
一句话结论在重症AKI(3期)患者中,常规及新型生物标志物均未能满意预测72小时内启动RRT的循证标准或MAKE60。

MARKISIO是AKIKI2试验的辅助研究,纳入256例需要侵入性机械通气或血管升压药的严重AKI(3期)患者,在发生严重AKI后12小时内采集血和尿样本,评估常规血清标志物(pH、血钾、血肌酐)及新型尿/血清标志物(CCL14、KIM1、烟酰胺及其代谢物、cDPP3、血浆脑啡肽原A 119-159)对主要终点(72小时内达到精确的RRT启动标准)的预测价值。101例(39%)在72小时内达到至少一项RRT启动标准或死亡。没有生物标志物对主要终点表现出满意的预测性能,也没有新型标志物与MAKE60发生显著相关。多变量分析中,SAPSIII和D0血清钾水平与MAKE60发生显著相关。结论认为,在循证RRT启动标准下,所测试的生物标志物可能无法有效指导RRT启动。

要点

  • 在严重AKI(3期)需要机械通气或血管升压药的患者中,39%(101/256)在72小时内达到至少一项RRT启动标准或死亡,但常规及新型生物标志物均未满意预测该主要终点。
  • 没有一种新型生物标志物(CCL14、KIM1、烟酰胺及其代谢物、cDPP3、血浆脑啡肽原A 119-159)与MAKE60发生显著相关。
  • 多变量分析显示,SAPSIII和D0血清钾水平与MAKE60发生显著相关。
  • 基于循证RRT启动标准,所测试的生物标志物可能无法有效指导严重AKI患者的RRT启动决策。

适用人群与场景

  • AKIKI2试验的辅助研究人群:严重AKI(3期)且接受侵入性机械通气或血管升压药的患者。

诊断标准与关键阈值

  • 主要终点为严重AKI发生后72小时内达到精确的RRT启动标准。
  • MAKE60为复合终点(原文未具体列出组成部分)。

研究设计与关键结果

  • 研究类型:AKIKI2试验的辅助研究;样本量256例;人群为严重AKI(3期)接受侵入性机械通气或血管升压药的患者。
  • 主要终点:101例(39%)在72小时内达到至少一项RRT启动标准或死亡;没有生物标志物对主要终点表现出满意的预测性能。
  • 关键次要终点:没有新型生物标志物与MAKE60发生显著相关;多变量分析中SAPSIII和D0血清钾水平与MAKE60发生显著相关。

证据类型、等级与局限

  • 证据类型:随机对照试验(AKIKI2)的辅助研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在严重AKI(3期)接受机械通气或血管升压药的患者中,所测试的常规及新型生物标志物可能无法有效指导RRT启动决策。
  • 作者认为,鉴于循证RRT启动标准,所测试的生物标志物可能无法有效指导RRT启动。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Predicting the need for renal replacement therapy (RRT) in acute kidney injury (AKI) remains challenging. The utility of biomarkers was explored during previous studies which were biased as RRT indications relied on clinician opinion rather than evidence. Those studies preceded trials that clarified RRT initiation criteria. We aimed to assess biomarkers in predicting criteria for RRT initiation in severe AKI patients.

MATERIAL AND METHODS: This is an ancillary study of the AKIKI2 trial. Patients with severe AKI (stage 3) receiving invasive mechanical ventilation and/or vasopressors were included. Blood and urine samples were collected within 12 h after the occurrence of severe AKI when feasible, depending on the availability of trained research staff and appropriate sample storage infrastructure. The primary endpoint was the onset of precise criteria for RRT initiation within 72 h after severe AKI. We analyzed routine serum biomarkers (pH, serum potassium, serum creatinine) and novel urinary and serum biomarkers (CCL14, KIM1, nicotinamide and its metabolites, cDPP3, plasma proenkephalin A 119-159).

RESULTS: Among the 256 patients, 101 (39%) met at least one criterion for RRT initiation or died within 72 h. No biomarker demonstrated satisfactory predictive performance for the primary endpoint. No novel biomarker was significantly associated with the occurrence of MAKE60. In multivariable analysis, 'SAPSIII' and 'Serum potassium level at D0' were significantly associated with the occurrence of MAKE60.

CONCLUSION: Neither routine nor novel biomarkers demonstrated conclusive predictive accuracy for the need for RRT in severe AKI patients. Given evidence-based criteria for initiating RRT, the tested biomarkers may not effectively guide RRT initiation.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Chaïbi K, Picod A, Boubaya M, et al. Biomarkers in acute kidney injury settings to predict interventions and outcomes: the MARKISIO study. Crit Care. 2025. PMID: 40394608. doi:10.1186/s13054-025-05439-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。